As an acknowledged antibody service provider, Creative Biolabs can offer various IVD (in vitro diagnostic) antibody development services to help our customers obtain antibodies with high specificity and affinity contributing to your research and projects successfully. Especially, Creative Biolabs offers high-quality antibody development services for diagnostic applications targeting UH-RA.9 as a potential biomarker for rheumatoid arthritis.

Early Diagnosis of Rheumatoid Arthritis

Early diagnosis and treatment have been recognized as essential to improve clinical outcomes in patients with early rheumatoid arthritis. However, diagnosis is somewhat difficult in the early stages of the disease because the diagnostic criteria were developed from data obtained in patients with established rheumatoid arthritis and therefore are not readily applicable.

Finding the ultimate biomarker for rheumatoid arthritis /rheumatoid disease is like a proverbial pot of gold at the end of a rainbow – except there’s no rainbow. If there is one essential biomarker, that could lead to tests that indicate who has the disease and how active it is, while providing clues to a cure. Meanwhile, people living with Rheumatoid Disease (PRD) suffer long delays in diagnosis and difficulties obtaining adequate treatment.

UH-RA.9 marker- Creative Biolabs

Novel UH-RA.9 Biomarker for Rheumatoid Arthritis

Recent researches report that autoantibodies against novel UH-RA peptides (UH-RA.1, UH-RA.9, UH-RA.14 and UH-RA.21) have been identified as candidate biomarkers for patients with rheumatoid arthritis (RA) who are seronegative for the current diagnostic markers rheumatoid factor and anticitrullinated protein antibodies. The detection of antibody reactivity against our candidate biomarkers in 37% of early and 26% of seronegative RA patients implies that these biomarkers can be of additional value to the current diagnostic biomarkers for RA, with most promising results for UH-RA.9. Our biomarkers may, therefore, contribute to an improved early diagnosis of RA. Significant associations with inflammatory factors and disease activity indicate an important prognostic potential as well.

IVD Antibody Development Services for UH-RA.9 Marker

The current emphasis in the field is to diagnose patients as early as possible so we can treat to target and improve outcomes. Patients who are seronegative for rheumatoid factor and/or anticitrullinated protein antibody are at risk of being neglected Identifying biomarkers to enable the early diagnosis of RA will help close the gap and identify more patients who are candidates for treatment. With our versatile IVD platform, Creative Biolabs is proud to develop novel UH-RA.9-specific antibody from scratch to commercial IVD kit (we can also start with provided antibody candidates).

Creative Biolabs is one of the forward-looking antibody research institution and provider who leads the development of the era while offering the best service to the customers around the world. Our seasoned experts in antibody research and development are pleased to provide IVD antibody development services for UH-RA.9 Marker. We have extensive experience in generating IVD antibodies. Please do not hesitate to contact us for more details.



Online Inquiry

Name:
*Phone:
*E-mail Address:
*Service & Products Interested:
Project Description:
*Verification Code:
Please input "biolabs"(case insensitive) as verification code.

Contact Us

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email:

Follow us on:
Copyright ©2011 - 2019 Creative Biolabs.